BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Jianying Liu; Yang Liu; Hongjie Xia; Jing Zou; Scott C. Weaver; Kena A. Swanson; Hui Cai; Mark Cutler; David Cooper; Alexander Muik; Kathrin U. Jansen; Uğur Şahin; Xuping Xie; Philip R. Dormitzer; Pei‐Yong Shi

doi:10.1038/s41586-021-03693-y

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Jianying Liu(The University of Texas Medical Branch at Galveston), Yang Liu(The University of Texas Medical Branch at Galveston), Hongjie Xia(The University of Texas Medical Branch at Galveston), Jing Zou(The University of Texas Medical Branch at Galveston), Scott C. Weaver(The University of Texas Medical Branch at Galveston), Kena A. Swanson(Pfizer (United States)), Hui Cai(Pfizer (United States)), Mark Cutler(Pfizer (United States)), David Cooper(Pfizer (United States)), Alexander Muik(BioNTech (Germany)), Kathrin U. Jansen(Pfizer (United States)), Uğur Şahin(BioNTech (Germany)), Xuping Xie(The University of Texas Medical Branch at Galveston), Philip R. Dormitzer(Pfizer (United States)), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston)

Nature

June 10, 2021

10.1038/s41586-021-03693-y

Cited by 380Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis